Merck CEO sees Keytruda in pole position in cancer race

DAVOS, Switzerland (Reuters) - Merck & Co's Keytruda cancer drug, which last week won a speedy review from U.S. regulators for use with chemotherapy in lung cancer, is in an increasingly strong position in a fiercely competitive market, the company's CEO said on Thursday.